Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dicerna Pharmaceutic (DRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 720,993
  • Shares Outstanding, K 52,820
  • Annual Sales, $ 2,280 K
  • Annual Income, $ -60,050 K
  • 36-Month Beta 2.34
  • Price/Sales 316.65
  • Price/Cash Flow N/A
  • Price/Book 7.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.07 +13.09%
on 06/19/18
14.93 -8.57%
on 06/05/18
+0.09 (+0.66%)
since 05/22/18
3-Month
8.71 +56.72%
on 04/02/18
15.80 -13.61%
on 05/15/18
+2.26 (+19.84%)
since 03/22/18
52-Week
2.69 +407.43%
on 08/22/17
15.80 -13.61%
on 05/15/18
+10.54 (+338.91%)
since 06/22/17

Most Recent Stories

More News
Dicerna Set to Join the Russell 3000(R) and Russell 2000(R) Indexes

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company is set to join...

DRNA : 13.65 (+4.36%)
Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

Stock Research Monitor: DARE, DRNA, and EGLT

DRNA : 13.65 (+4.36%)
DERM : 10.48 (-2.51%)
DARE : 1.29 (-2.27%)
Dicerna Doses First Primary Hyperoxaluria Patient with DCR-PHXC in Group B Portion of PHYOX Phase 1 Clinical Trial

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company has dosed the...

DRNA : 13.65 (+4.36%)
Dicerna Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Dicerna Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern Time....

DRNA : 13.65 (+4.36%)
Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results...

DRNA : 13.65 (+4.36%)
New Report Released on Growing Biotech Sector

FN Media Group Presents Microcapspeculators.com News Commentary

DRNA : 13.65 (+4.36%)
PPCHD : 1.2000 (+20.00%)
IONS : 42.95 (+1.85%)
PPCB : 0.0639 (+3.23%)
CASI : 6.28 (+9.98%)
INSM : 26.43 (-1.78%)
Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the company has resolved...

DRNA : 13.65 (+4.36%)
Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president...

DRNA : 13.65 (+4.36%)
Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Goldfield Corp. (NYSE:GV),...

DRNA : 13.65 (+4.36%)
CARO : 45.05 (+0.78%)
WSBC : 46.91 (-0.64%)
TSC : 26.25 (-0.19%)
DCPH : 39.55 (-12.01%)
GV : 4.30 (+1.18%)
Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operating Results and Provides Corporate Update

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results...

DRNA : 13.65 (+4.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRNA with:

Business Summary

Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 14.24
1st Resistance Point 13.95
Last Price 13.65
1st Support Level 13.20
2nd Support Level 12.74

See More

52-Week High 15.80
Last Price 13.65
Fibonacci 61.8% 10.79
Fibonacci 50% 9.24
Fibonacci 38.2% 7.70
52-Week Low 2.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar